Global costs, health benefits, and economic benefits of scaling up treatment and imaging modalities for survival of 11 cancers: a simulation-based analysis

Treatment, imaging, and quality of care could avert 12% of cancer deaths globally, ranging from 2% in high-income countries to 38% in low-income nations. Globally, scale-up would cost an additional $232bn but produce $2bn in lifetime economic benefits.

High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial

This open-label, randomised, phase 2 trial was done at 22 public hospitals in Norway, Denmark, and Sweden. At 2 years, 66% of patients in the 60 Gy group were alive, compared with 39% in the 45 Gy group. The higher radiotherapy dose of 60 Gy resulted in a substantial survival improvement.

The impact of the COVID-19 pandemic on radiotherapy services in England, UK: a population-based study

In 2020, mean weekly radiotherapy courses fell by 19% in April, 6% in May, and 11% in June compared with corresponding months in 2019. The largest reduction from 2019 to 2020 in treatment courses was for prostate cancer and skin cancer.

Identification of novel risk loci and causal insights for sporadic Creutzfeldt-Jakob disease: a genome-wide association study

Human prion diseases are rare and usually rapidly fatal neurodegenerative disorders. Most common is sporadic Creutzfeldt-Jakob disease (sCJD) Variants in the PRNP gene that encodes prion protein are strong risk factors for sCJD.

Neurological disease in adults with Zika and chikungunya virus infection in Northeast Brazil: a prospective observational study

Since 2015, the arthropod-borne viruses (arboviruses) have spread across the Americas causing outbreaks. These outbreaks have been accompanied by increases in immune-mediated and infectious neurological diseases. Patients with Guillain-Barré syndrome who had chikungunya dual infection had the more aggressive disease.

Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial

We aimed to assess the safety and efficacy of galcanezumab, an antibody to calcitonin gene-related peptide. The primary endpoint was the overall mean change from baseline in a number of monthly migraine headache days during the 3-month treatment period.

Neuropathology of patients with COVID-19 in Germany: a post-mortem case series

It is unclear whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) gains access to the CNS. We investigated the brain tissue of patients who died from COVID-19 for glial responses, inflammatory changes, and the presence of SARS- CoV- 2 in the brain. There was no evidence of CNS damage directly caused by the virus. The generalisability of these findings needs to be validated in future studies.

Monogenic variants in dystonia: an exome-wide sequencing study

Dystonia is a clinically and genetically heterogeneous condition that occurs in isolation or in combination with other movement disorders. We sequenced the exomes of 764 individuals with dystonia and 346 healthy parents who were recruited between June 1, 2015, and July 31, 2019. 104 (65%) of the 160 detected variants affected genes which are associated with neurodevelopmental disorders.